Project Grant R01CA288301
Award Date
9/1/24
Completion Date
8/31/28
Dollars Obligated
$300K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Vermillion, SD 57069, USA
Similar Awards
This $753,446 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) aims to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in Boston, Hispanic immigrants in Florida, and Hawaiian Natives/Pacific Islanders in Hawaii. The intervention combines education and quality improvement methods using a mechanism called Performance...
This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
The National Cancer Institute (NCI) awarded a $328,822 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Implenomics Llcs, a minority-owned, women-owned small business located in Marblehead, Massachusetts. The grant, effective September 20, 2024 through August 31, 2026, will fund the development and pilot testing of the Integrated Cancer Awareness Network (ICAN), an innovative mHealth platform. ICAN will provide cancer risk, symptom, and screening education to...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,226,040 to the Regents of the University of Minnesota to conduct a randomized clinical trial of a culturally-tailored suite of smoking cessation resources for American Indian persons. The key objectives are to: Co-create a culturally-aligned website, "Smokefree.gov for Natives", to serve as the landing page for digital cessation resources tailored for American...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, aims to optimize a bundled breast and cervical cancer screening program in Cameroon. The $192,780 award to the University of Alabama at Birmingham (UAB) supports implementation science research to 1) evaluate the reach and effectiveness of the screening program across stationary and mobile clinics, 2) identify implementation outcomes of acceptability, appropriateness,...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The grant aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMIC). The key goals of the project are to: 1) Modify the IRISTM...
This $643,363 Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), will support a hybrid type III effectiveness-implementation trial to test best practices for deploying a "screen and treat" approach to cervical cancer screening using self-collected HPV DNA testing within HIV care and treatment facilities in Mozambique. The primary outcome is to increase the number of women screened and treated for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $547,047 to Georgetown University to test the bundling of multicancer screening, genetic services navigation, and other interventions to improve cancer screening rates and reduce health disparities among non-Hispanic Black and Hispanic women. The project aims to address patient- and organization-level barriers that limit access to cancer screening and genetic testing,...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...